Published Date: 26 Apr 2023
One million Americans currently have Parkinson's disease, and another 90,000 are diagnosed with it each year. It is currently the second most prevalent neurodegenerative disease in the country. And it's moving up to No. 1. However, few people are familiar with Parkinson's.
Read Full NewsDrug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.
Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.
1.
An inhibitor of JAK1 exhibits "remarkable" activity in T-cell lymphoma.
2.
In Biochemically Recurrent Nonmetastatic Prostate Cancer, Apalutamide Presents Its Argument.
3.
Decrease seen in in situ breast cancer since 2009
4.
Should the UK introduce targeted prostate cancer screening? The case for and against
5.
Safe and acceptable telehealth suicide prevention program.
1.
The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective
2.
How EPCORITAMAB is Revolutionizing the Treatment of Cancer
3.
Unraveling the Complexities of Embryonal Carcinoma: A New Hope for Treatment
4.
All You Need To Know About Melanoma Maligna: Causes, Symptoms & Treatment
5.
Targeting Iron Recycling Pathways in Hematologic Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation